Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with ...
AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
Please provide your email address to receive an email when new articles are posted on . Clinicians should have a low threshold for stopping interleukin-2 when treating with tumor-infiltrating ...
Nkarta Therapeutics’ off-the-shelf natural killer cell therapy appears to be most effective against blood cancer when used with a specific lymphodepletion regimen. But that’s not what most patients ...
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile ...
Clinical data readout from Phase 1 APOLLO study expected later this year HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing ...
A hallmark characteristic of CAR T therapy is that it is individually crafted. Each patient receives a unique cancer-fighting infusion made from their own immune cells. The crucial process of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results